Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105385 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Darius Čereškevičius und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 15, LT 50103 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Atorvastatin, Acute Coronary Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funds of Lithuanian University of Health Sciences "Mokslo fondas", funds of Lithuanian University of Health Sciences “Mokslo fondas”.
Abstract (Originalsprache)
The effectiveness of lipid-lowering therapies may be insufficient in high-risk cardiovascular patients and depends on the genetic variability of drug-metabolizing enzymes. Customizing statin therapy, including treatment with atorvastatin, may improve clinical outcomes. Currently, there is a lack of guidelines allowing the prediction of the therapeutic efficacy of lipid-lowering statin therapy. This study aimed to determine the effects of clinically significant gene variants of CYP2C19 on atorvastatin therapy in patients with acute coronary syndromes. In total, 92 patients with a confirmed diagnosis of ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) were sequenced for target regions within the CYP2C19 gene on the Illumina Miniseq system. The CYP2C19 poor metabolizer phenotype (carriers of CYP2C19*2, CYP2C19*4, and CYP2C19*8 alleles) was detected in 29% of patients. These patients had significantly lower responses to treatment with atorvastatin than patients with the normal metabolizer phenotype. CYP2C19-metabolizing phenotype, patient age, and smoking increased the odds of undertreatment in patients (∆LDL-C (mmol/L) < 1). These results revealed that the CYP2C19 phenotype may significantly impact atorvastatin therapy personalization in patients requiring LDL lipid-lowering therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 15, LT 50103 Kaunas, Lithuania.
- Department of Cardiology, Kaunas Hospital of the Lithuanian University of Health Sciences, Hipodromo 13, LT 45130 Kaunas, Lithuania.
- Institute of Microbiology and Virology, Lithuanian University of Health Sciences, Eivenių 4, LT 50161 Kaunas, Lithuania.
- Institute of Pharmaceutical Technologies, Sukileliu 13, LT 50103 Kaunas, Lithuania.
- Department of Cardiology, Lithuanian University of Health Sciences, Eivenių 2, LT 50009 Kaunas, Lithuania.
ORCID-Profile: Ali Aldujeli, Vytautas Raškevičius, Ieva Čiapienė, Vacis Tatarūnas
Förderung
- Funds of Lithuanian University of Health Sciences "Mokslo fondas"
- funds of Lithuanian University of Health Sciences “Mokslo fondas”
Zitieren
APA
Čereškevičius, D., Zabiela, V., Aldujeli, A., Lesauskaitė, V., Zubielienė, K., Raškevičius, V., Čiapienė, I., Žaliaduonytė, D., Giedraitienė, A., Žvikas, V., Jakštas, V., Skipskis, V., Dobilienė, O., Šakalytė, G., & Tatarūnas, V. (2024). Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105385
Vancouver
Čereškevičius D, Zabiela V, Aldujeli A, Lesauskaitė V, Zubielienė K, Raškevičius V, et al. Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105385
BibTeX
@article{erekeviius2024,
author = {Čereškevičius, Darius and Zabiela, Vytautas and Aldujeli, Ali and Lesauskaitė, Vaiva and Zubielienė, Kristina and Raškevičius, Vytautas and Čiapienė, Ieva and Žaliaduonytė, Diana and Giedraitienė, Agnė and Žvikas, Vaidotas and Jakštas, Valdas and Skipskis, Vilius and Dobilienė, Olivija and Šakalytė, Gintarė and Tatarūnas, Vacis},
title = {Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105385}
}
EUVIMED